trial · primary record
pTTL
Colorectal Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 16 |
| Primary completion | 2030-12 |
| Primary endpoint | Safety of pTTL administration, as determined by assessment of incidence and severity of adverse events (AE). Immunological AEs and AEs known to be associated with T cell therapies will be classified as AEs of special interest (AESI). |
| Registry ID | NCT05908643 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:38:26.104Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05908643
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.